Gland Pharma Ltd. - Research Center
543245 GLAND Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Sales | 1,894.74 | 1,905.21 | 2,166.34 | 2,234.37 | 1,715.71 |
| Operating profit | 606.46 | 565.44 | 697.70 | 812.94 | 710.32 |
| Interest | 2.51 | 2.62 | 3.22 | 2.03 | 1.23 |
| Gross profit | 680.27 | 702.84 | 805.39 | 923.95 | 761.52 |
| EPS (Rs) | 27.03 | 28.48 | 34.05 | 39.75 | 32.61 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Other income | 76.32 | 140.02 | 110.90 | 113.04 | 52.43 |
| Stock adjustment | -43.23 | 45.63 | -32.35 | 69.04 | -161.66 |
| Raw material | 848.43 | 845.18 | 1,067.54 | 979.33 | 845.90 |
| Power and fuel | - | - | 25.13 | - | - |
| Employee expenses | 202.79 | 199.16 | 175.68 | 162.89 | 150.90 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 280.29 | 249.80 | 232.65 | 210.18 | 170.26 |
| Provisions made | - | - | - | - | - |
| Depreciation | 79.22 | 71.58 | 58.91 | 51.39 | 48.89 |
| Taxation | 155.95 | 162.17 | 187.12 | 219.77 | 180.18 |
| Net profit / loss | 445.11 | 469.08 | 559.36 | 652.80 | 532.45 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 16.47 | 16.47 | 16.43 | 16.42 | 16.33 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 32.01 | 29.68 | 32.21 | 36.38 | 41.40 |
| GPM (%) | 34.51 | 34.36 | 35.37 | 39.36 | 43.07 |
| NPM (%) | 22.58 | 22.94 | 24.56 | 27.81 | 30.11 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis